1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Pulmonary Tuberculosis - Pipeline Review, H1 2014

Pulmonary Tuberculosis - Pipeline Review, H1 2014

  • April 2014
  • -
  • Global Markets Direct
  • -
  • 58 pages

Pulmonary Tuberculosis - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Pulmonary Tuberculosis - Pipeline Review, H1 2014’, provides an overview of the Pulmonary Tuberculosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Tuberculosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Tuberculosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pulmonary Tuberculosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pulmonary Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Tuberculosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Tuberculosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Tuberculosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Pulmonary Tuberculosis - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Pulmonary Tuberculosis Overview 7
Therapeutics Development 8
Pipeline Products for Pulmonary Tuberculosis - Overview 8
Pipeline Products for Pulmonary Tuberculosis - Comparative Analysis 9
Pulmonary Tuberculosis - Therapeutics under Development by Companies 10
Pulmonary Tuberculosis - Therapeutics under Investigation by Universities/Institutes 11
Pulmonary Tuberculosis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Pulmonary Tuberculosis - Products under Development by Companies 15
Pulmonary Tuberculosis - Products under Investigation by Universities/Institutes 16
Pulmonary Tuberculosis - Companies Involved in Therapeutics Development 17
Johnson and Johnson 17
Sequella, Inc. 18
AstraZeneca PLC 19
Microbion Corporation 20
Pulmonary Tuberculosis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
bedaquiline fumarate - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
SQ-109 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
sutezolid - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
AZD-5847 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
PA-824 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
rBCG30 Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
SQ-609 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
r30 Vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
methionine sulfoximine - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Live Recombinant Booster Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Pulmonary Tuberculosis - Recent Pipeline Updates 46
Pulmonary Tuberculosis - Dormant Projects 51
Pulmonary Tuberculosis - Product Development Milestones 52
Featured News and Press Releases 52
Dec 20, 2013: SIRTURO Receives Positive Opinion from the Committee for MedicinalProducts for Human Use as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis 52
Jul 26, 2013: Otsuka Receives Opinion from CHMP on Delamanid 52
Jul 02, 2012: Janssen Submits New Drug Application To FDA For Bedaquiline For Multi-Drug Resistant Tuberculosis Treatment 53
Oct 18, 2010: Sequella Receives International Support For Phase II Clinical Trials Of SQ109 For Treatment Of Adult Pulmonary Tuberculosis 54
Oct 18, 2005: The Global Alliance for TB Drug Development Announces Phase II Trials To Study Potential Of Moxifloxacin To Shorten TB Treatment Partners Commit To Affordable Pricing For Patients In The Developing World 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables

Number of Products under Development for Pulmonary Tuberculosis, H1 2014 8
Number of Products under Development for Pulmonary Tuberculosis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Pulmonary Tuberculosis - Pipeline by Johnson and Johnson, H1 2014 17
Pulmonary Tuberculosis - Pipeline by Sequella, Inc., H1 2014 18
Pulmonary Tuberculosis - Pipeline by AstraZeneca PLC, H1 2014 19
Pulmonary Tuberculosis - Pipeline by Microbion Corporation, H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Stage and Target, H1 2014 23
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Pulmonary Tuberculosis Therapeutics - Recent Pipeline Updates, H1 2014 46
Pulmonary Tuberculosis - Dormant Projects, H1 2014 51

List of Figures

Number of Products under Development for Pulmonary Tuberculosis, H1 2014 8
Number of Products under Development for Pulmonary Tuberculosis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 22
Number of Products by Stage and Top 10 Target, H1 2014 23
Number of Products by Top 10 Mechanism of Action, H1 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 25
Number of Products by Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.